Gyon Technologies Capital Management, LP Travere Therapeutics, Inc. Transaction History

Gyon Technologies Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $474,383 - $671,379	25,684 Added 205.83%	38,162 $802,000
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $251,116 - $313,813	-10,961 Reduced 46.76%	12,478 $307,000
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $132,340 - $189,663	6,320 Added 36.92%	23,439 $568,000
Q1 2022 May 12, 2022	SELL	$23.61 - $30.6 $2.25 Million - $2.92 Million	-95,459 Reduced 84.79%	17,119 $441,000
Q4 2021 Feb 11, 2022	BUY	$24.34 - $31.17 $786,255 - $1.01 Million	32,303 Added 40.24%	112,578 $3.49 Million
Q3 2021 Nov 18, 2021	BUY	$12.98 - $25.03 $1.04 Million - $2.01 Million	80,275 New	80,275 $1.95 Million

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.